David M. Kornhauser

3.3k total citations
48 papers, 2.3k citations indexed

About

David M. Kornhauser is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Pharmacology. According to data from OpenAlex, David M. Kornhauser has authored 48 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Surgery and 10 papers in Pharmacology. Recurrent topics in David M. Kornhauser's work include Analytical Methods in Pharmaceuticals (7 papers), Diabetes Treatment and Management (7 papers) and HIV/AIDS drug development and treatment (6 papers). David M. Kornhauser is often cited by papers focused on Analytical Methods in Pharmaceuticals (7 papers), Diabetes Treatment and Management (7 papers) and HIV/AIDS drug development and treatment (6 papers). David M. Kornhauser collaborates with scholars based in United States, Germany and Sweden. David M. Kornhauser's co-authors include David G. Shand, N. Vachharajani, Bernard J. Komoroski, Marc Pfister, David W. Boulton, G. Wilkinson, Feng Yan, Otakar R. Hubschmann, G. W. K. Moore and Peter W. Stacpoole and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

David M. Kornhauser

48 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David M. Kornhauser United States	24	800	671	549	312	290	48	2.3k
James F. McLeod United States	28	487 0.6×	460 0.7×	274 0.5×	234 0.8×	89 0.3×	52	1.9k
Keith G. Tolman United States	31	632 0.8×	466 0.7×	669 1.2×	242 0.8×	115 0.4×	83	3.2k
Mark E. Cooper Australia	34	1.0k 1.3×	1.4k 2.0×	443 0.8×	253 0.8×	861 3.0×	67	4.6k
Stephan Krähenbühl Switzerland	32	347 0.4×	988 1.5×	446 0.8×	236 0.8×	286 1.0×	100	3.1k
Robert J. Straka United States	30	437 0.5×	709 1.1×	542 1.0×	162 0.5×	350 1.2×	109	2.6k
Hirotoshi Echizen Japan	28	460 0.6×	373 0.6×	432 0.8×	387 1.2×	373 1.3×	100	3.0k
Walter Ziegler Switzerland	25	733 0.9×	404 0.6×	469 0.9×	419 1.3×	588 2.0×	82	2.5k
Kazuko Nakagawa Japan	32	339 0.4×	588 0.9×	454 0.8×	216 0.7×	383 1.3×	117	2.8k
James M. Luther United States	31	1.2k 1.5×	757 1.1×	595 1.1×	259 0.8×	556 1.9×	71	2.7k
Diane K. Jorkasky United States	27	350 0.4×	341 0.5×	353 0.6×	144 0.5×	425 1.5×	68	1.7k

Countries citing papers authored by David M. Kornhauser

Since Specialization

Citations

This map shows the geographic impact of David M. Kornhauser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Kornhauser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Kornhauser more than expected).

Fields of papers citing papers by David M. Kornhauser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Kornhauser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Kornhauser. The network helps show where David M. Kornhauser may publish in the future.

Co-authorship network of co-authors of David M. Kornhauser

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Kornhauser. A scholar is included among the top collaborators of David M. Kornhauser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Kornhauser. David M. Kornhauser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Boulton, David W., Georgia Kollia, Suresh Mallikaarjun, & David M. Kornhauser. (2012). Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. Journal of Clinical Pharmacy and Therapeutics. 37(5). 565–570. 9 indexed citations

2.

Boulton, David W., Georgia Kollia, Suresh Mallikaarjun, & David M. Kornhauser. (2012). Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. Journal of Clinical Pharmacy and Therapeutics. 1 indexed citations

3.

Patel, Chirag, Li Li, Suzette Girgis, et al.. (2011). Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. SHILAP Revista de lepidopterología. 3. 13–13. 39 indexed citations

4.

Patel, Chirag G., David M. Kornhauser, N. Vachharajani, et al.. (2011). Saxagliptin, a potent, selective inhibitor of DPP‐4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obesity and Metabolism. 13(7). 604–614. 18 indexed citations

5.

Boulton, David W., Li Li, Ernst U. Frevert, et al.. (2011). Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin. Clinical Pharmacokinetics. 50(4). 253–265. 85 indexed citations

6.

Findling, Robert L., Ralph E. Kauffman, Floyd R. Sallee, et al.. (2009). An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder. Journal of Child and Adolescent Psychopharmacology. 19(4). 431–439. 38 indexed citations

7.

Boulton, David W., Angela Tang, Chirag Patel, et al.. (2009). Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment. 20. 7 indexed citations

8.

Komoroski, Bernard J., N. Vachharajani, David W. Boulton, et al.. (2009). Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects. Clinical Pharmacology & Therapeutics. 85(5). 520–526. 288 indexed citations

9.

Boulton, David W., et al.. (2009). P0586 A COMPARISON OF THE SINGLE-DOSE PHARMACOKINETICS AND SAFETY OF SAXAGLIPTIN IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY SUBJECTS. European Journal of Internal Medicine. 20. S194–S194. 4 indexed citations

10.

Komoroski, Bernard J., et al.. (2009). Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus. Clinical Pharmacology & Therapeutics. 85(5). 513–519. 338 indexed citations

11.

Pieniaszek, Henry J., Sherwin K. B. Sy, William F. Ebling, et al.. (2002). Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers. The Journal of Clinical Pharmacology. 42(7). 738–753. 13 indexed citations

12.

Fossler, Michael J., William F. Ebling, David M. Kornhauser, et al.. (2002). Integrated Pharmacokinetic/Pharmacodynamic Model of XV459, a Potent and Specific GPIIb/IIIa Inhibitor, in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 42(12). 1326–1334. 7 indexed citations

13.

Barditch‐Crovo, Patricia, Brent G. Petty, John G. Gambertoglio, et al.. (1998). The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet. Antiviral Research. 38(3). 209–212. 2 indexed citations

14.

Fiske, William D., et al.. (1997). Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate in healthy volunteers. 37. 275. 3 indexed citations

15.

Benedek, Irma H., et al.. (1995). Variability in the Pharmacokinetics and Pharmacodynamics of Low Dose Aspirin in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 35(12). 1181–1186. 112 indexed citations

16.

Kornhauser, David M., et al.. (1992). Thermospray liquid chromatographic—mass spectrometric analysis of anti-AIDS nucleosides: quantification of 2',3'-dideoxycytidine in plasma samples. Journal of Chromatography B Biomedical Sciences and Applications. 577(2). 299–304. 12 indexed citations

17.

Cantú, Thomas G., et al.. (1990). Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrobial Agents and Chemotherapy. 34(7). 1459–1461. 22 indexed citations

18.

Hubschmann, Otakar R. & David M. Kornhauser. (1983). Effects of intraparenchymal hemorrhage on extracellular cortical potassium in experimental head trauma. Journal of neurosurgery. 59(2). 289–293. 31 indexed citations

19.

Vestal, Robert E., David M. Kornhauser, & David G. Shand. (1980). Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines.. Journal of Pharmacology and Experimental Therapeutics. 214(1). 106–111. 41 indexed citations

20.

Kornhauser, David M., Peter A. J. Adam, & Robert Schwartz. (1970). Glucose Production and Utilization in the Newborn Puppy. Pediatric Research. 4(2). 120–128. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact